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Objective
To establish the prevalence, severity and factors associated with the HIV lipodystrophy syndrome.
Methods
Cross-sectional study of lipodystrophy conducted in high HIV caseload primary care sites and HIV
outpatient clinics. A subset of patients was examined using dual energy X-ray absorptiometry
(DEXA) and single cut abdominal computerized tomography (CT) at the L4 vertebral level to quantify
regional and total body fat. Factors associated with lipodystrophy, lipoatrophy and lipohypertrophy
were assessed using multiple logistic regression based on assignment of cases and non-cases.
Results
One thousand, three hundred and forty-eight patients (95% male) were surveyed, 20% had AIDS, the
mean CD4 lymphocyte count was 486 cells/mL, and 55% had o500 HIV-1 RNA copies/mL. Most
participants (87%) had previously received or were currently receiving combination antiretroviral
therapy, 73% with at least one protease inhibitor (PI) and 14% a non-PI-containing regimen.
Lipodystrophy prevalence was 53% and of these, 55% reported both peripheral lipoatrophy and
central lipohypertrophy, 31% experienced peripheral lipoatrophy only and 14% had central
lipohypertrophy only. The prevalence of any body habitus change was 62% in PI-experienced
patients, 33% in PI-naive patients and 21% in antiretroviral-naive patients. Lipodystrophy severity
was less in antiretroviral-naive patients and most severe in PI-experienced patients. Increasing
severity of lipodystrophy was both positively and significantly correlated with elevated liver
enzymes, decreased testosterone levels, decreased skin-fold thickness, lower levels of total and
peripheral fat (DEXA) and higher levels of visceral fat (CT). Lipodystrophy was also significantly
associated with increasing age, symptomatic HIV disease, effective viral suppression, and increasing
duration of therapy with both nucleoside reverse transcriptase inhibitors and PIs.
Conclusions
The prevalence and severity of lipodystrophy reflects both length and type of treatment with
antiretroviral therapy and is associated with decreased testosterone, increases in liver enzymes and
greater suppression of HIV RNA. The reports of lipodystrophy in a small percentage of antiretroviral-
naive patients suggests that factors other than antiretroviral therapy may be involved in the
aetiology of this syndrome or that some conditions, such as wasting or age-associated obesity, may
mimic lipoatrophy and lipohypertrophy, respectively.
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Introduction
Combination antiretroviral therapy for HIV infection is
frequently associated with lipodystrophy (peripheral lipoa-
trophy, central lipohypertrophy, lipomata) and various
metabolic abnormalities including hyperlipidemia, insulin
resistance and lactic acidaemia [1–8]. Lipodystrophy is
generally observed months to years after initiation of
combination antiretroviral therapy [8]. These changes are
often seen in the presence of effective suppression of viral
replication and otherwise good health [4]. Some of the
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metabolic abnormalities, such as hypertriglyceridemia,
may predate antiretroviral therapy and be exacerbated
during therapy [9–11]. Lipodystrophy has been reported
more commonly in patients receiving protease inhibitor
(PI)-containing combinations [1, 4, 8, 12].
Published studies, to date, have found prevalence rates
varying from 18 to 83% and have identified differing
potential risk factors [1, 5, 7–9, 13, 14, 14, 15]. These
studies have linked lipodystrophy to one or more PI agent,
nucleoside analogue reverse transcriptase inhibitors
(NRTIs), or effective suppression of HIV replication. The
variable prevalence and factors associated with lipodystro-
phy reported in these studies may have occurred because
the studies had relatively small sample sizes and selected
cohorts, did not evaluate all potential aetiological factors,
did not include all possible treatment options, did not use
common diagnostic methods or objective data for quanti-
fying lipodystrophy and were performed at single sites. We
conducted a multicentre survey of HIV-infected Australian
adults to determine the prevalence and severity of
lipodystrophy and potential risk factors associated with
lipodystrophy. This survey was conducted using common
methodologies and encompassed a broad range of sites,
patient groups and assessed a comprehensive range of
potential aetiological factors in order to address these
potential weaknesses.
Methods
Patient population
The study recruited patients from 15 centres comprising
community (n5 7), sexual health (n5 2) and hospital
(n5 6) sites in Australia. These sites provide health care for
approximately 2200 HIV-infected patients. Consecutive
patients greater than 17 years of age with confirmed HIV
infection presenting to the study sites over a 6-month
period for routine outpatient care were invited to
participate. Patients were eligible to participate irrespective
of antiretroviral exposure.
Study design and data collection
The study was conducted from November 1998 to July
1999. The following clinical data were obtained cross-
sectionally: age, gender, HIV disease stage, personal and
family history of diabetes and cardiac disease, smoking,
anabolic steroid use, type and duration of all antiretroviral
agents and current exercise levels. Fasting lipid (triglycer-
ides, total and HDL cholesterol) and glycaemic parameters
(glucose, insulin, C-peptide), liver enzymes, total testoster-
one, CD4 lymphocyte counts and plasma HIV RNA were
performed at the time of assessment. Local laboratories
were used for all assessments.
Lipodystrophy assessments
Height, weight, waist and hip circumference were obtained
by standard methods [16]. A targeted physical examination
was conducted by the physician to evaluate any changes of
lipodystrophy. This included a specific assessment of
lipoatrophy in the periphery (face, arms, legs, buttocks
and venous prominence), and lipohypertrophy centrally
(abdomen, breasts, dorsocervical region as well as the
presence of lipomata at any site). Using a standardized
questionnaire, physicians subjectively graded any changes
present as either mild, moderate or severe, and numerical
scores were attached to lipodystrophy reports (05 none,
15mild, 25moderate, 35 severe) for a maximum possi-
ble score of 15 peripherally, 12 centrally and 27 overall [1].
At sites where staff were experienced in anthropometry
(n5 8), triceps, calf, supra-iliac crest and naso-labial fold
skin-fold thickness was recorded. The latter assessment,
which measures the thickness of the naso-labial fold at its
mid-point, is not a validated measure. Every fifth consent-
ing subject also underwent body composition studies using
dual X-ray absorptiometry (DEXA; Lunar DPXL, Madison,
WI) and single cut abdominal computerized tomography
(CT) performed at the mid-L4 level vertebral with a manual
calculation to estimate the areas of visceral adipose tissue
(VAT), subcutaneous adipose tissue (SAT) and total adipose
tissue (TAT). Standard protocols were used for all body
imaging studies [1, 2, 4]. All CT and DEXA scans were read
at local centres using standardized procedures. If a patient
declined body composition studies, the next consenting
patient was approached.
Definitions
Lipodystrophy was defined by the physician-assessed
presence of lipoatrophy or lipohypertrophy of any severity
in one or more body region (face, arms, legs and buttocks,
abdomen, breasts, dorsocervical region) or by the presence
of lipomata [1, 4]. Clinical HIV disease was categorized
using the Centers for Disease Control and Prevention
classification system. Assessment of exercise levels was
defined as sedentary (light physical activity foro2 h week),
low (light physical activity for 2–4 h per week), moderate
(light physical activity 44 h per week or vigorous activity
for 2–4 h per week), or high (highly vigorous physical
activity 44 h per week or regular exercise or competitive
sports several times per week) [16].
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Approvals
Human Research Ethics Committee approval for the study
was obtained for each site. Written, informed consent was
obtained from each participant.
Statistics
Comparisons between selected groups used the Mann–
Whitney U-test for continuous variables and Fisher’s exact
test for categorical variables. Factors associated with
lipodystrophy, lipoatrophy and lipohypertrophy were as-
sessed using multiple logistic regression based on assign-
ment of cases and non-cases. Factors assessed included age,
HIV disease stage, exercise levels, CD4 lymphocyte count,
plasma HIV RNA, and antiretroviral type and duration,
steroid use, metabolic and glycaemic parameters.
Relative associations between different antiretrovirals
and lipodystrophy were assessed in multivariate analyses.
These were analyzed by phenotype (any lipodystrophy,
lipoatrophy, lipohypertrophy) and by duration of therapy
in months, stratified less than or greater than the median.
For analysis, patients were categorized by exposure and
duration of exposure to various antiretroviral classes,
regardless of whether patients were receiving therapy at the
time of survey. The categories used were: (a) antiretroviral
naive, (b) past or current treatment with an NRTI with or
without an NNRTI, and (c) past or current treatment with a
PI in addition to an NRTI with or without an NNRTI.
Results
Study participants
Demographic and treatment data for the 1348 participants
are shown in Table 1. The cohort is consistent with the HIV
epidemic in Australia where 92.6% of all HIV infections
have occurred in men [17]. The number of survey
participants represent 67% of the estimated HIV-infected
patients from the participating sites and 11.5% of all known
existing HIV-infected adults in Australia at that time [17].
The lipodystrophy prevalence survey (LPS) data were
compared to data from the Australian HIV Observational
Database (AHOD) to determine consistency with the
broader HIV-affected community [18]. The LPS and AHOD
were found to be similar in terms of mean age (39.8 and 40
years, respectively), proportion of males (95% and 96%),
mean CD4 lymphocyte count (487 and 521 cells/mL),
undetectable viral load (55% and 46%), prior AIDS (20%
and 16%) and PI use (73% and 67%) [18]. Of those patients
who had received treatment with a PI in this survey
(n5 986), 239 (19%) were not currently taking PIs at the
time of the survey, with a median time since discontinua-
tion of 6 months.
Prevalence of lipodystrophy
The overall prevalence of physician-assessed lipodystrophy
was 53% (Table 2). A mixed phenotype was most prevalent
with 27% of the overall survey having both peripheral
lipoatrophy and central lipohypertrophy. Patients with either
lipoatrophy only or lipohypertrophy only accounted for 20%
and 6%, respectively. The most frequently reported affected
site was the face (45%), followed by legs (42%), abdomen
(39%), arms (39%), buttocks (36%), dorsocervical region
(4%) and lipomata (4%). Lipodystrophy was reported in 21%
(n5 35) of antiretroviral naive patients in this survey.
Peripheral lipoatrophy
The severity of peripheral lipoatrophy on physical exam-
ination was associated with significantly reduced skinfold
Table 1 Characteristics of survey participants
Total
(n5 1348)
Male
(n5 1280)
Female
(n5 68)
Age (mean, SD) 39.8 (11.5) 40 (12) 35 (7)
CD4 cells/mL (mean SD) 487 (434) 486 (441) 491 (272)
HIV RNA
mean log copies/mL (SD) 4.7 (1.04) 4.7 (1.04) 4.8 (1.02)
r500 copies/mL (n, %) 744 (55) 710 (55) 34 (50)
HIV disease category
A (n, %) 701 (52) 670 (52) 30 (44)
B (n, %) 376 (28) 345 (27) 30 (44)
C (n, %) 271 (20) 265 (21) 6 (12)
Antiretroviral exposure (n,%)
naive (n,%) 168 (12)
no protease inhibitor (n,%) 194 (14)
protease inhibitor (n,%) 986 (75)
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thickness, decreased hip circumference, and lower levels of
abdominal subcutaneous abdominal adipose tissue, total
fat and limb fat (Table 3). Patients with and without
peripheral lipoatrophy had similar levels of visceral
adipose tissue.
Central lipohypertrophy
Lipohypertrophy on physical exam was associated with
significantly greater waist circumference and visceral adipose
tissue (Table 4), but no differences were seen in subcutaneous
Table 2 Lipodystrophy prevalence and severity by phenotype and antiretroviral exposure
None
Lipoatrophy
(maximum score5 15)
Lipohypertrophy
(maximum score5 12)
Mixed
(maximum score5 27)
Any LD
(maximum score5 27)
ART Naive
% (n) 79 (132) 9 (15) 3 (6) 9 (15) 21 (36)
mean severity (SE) 3.6 (2.8) 1.6 (1.0) 7.7 (4.2) 5.0 (4.0)
NRTI/NNRTI (ever)
% (n) 68 (132) 16 (31) 6 (11) 10 (20) 32 (62)
mean severity (SE) 3.4 (2.5) 1.2 (0.6) 9.9 (4.8) 5.2 (4.7)
PI (ever)
% (n) 38 (375) 23 (225) 6 (63) 33 (326) 62 (611)
mean severity (SE) 4.3 (3.3) 1.7 (1.0) 8.6 (4.6) 6.3 (4.6)
All
% (n) 47 (639) 20 (271) 6 (80) 27 (361) 53 (709)
mean severity (SE) 4.1 (3.2) 1.7 (0.9) 8.6 (4.4) 6.1 (4.6)
Mean severity scores are derived from affected patients only; SE, standard error.
Table 3 Associations with maximal severity of lipodystrophy
Lipodystrophy Lipoatrophy Lipohypertrophy
none mild mod sev P-trend none mild mod sev P-trend none mild mod sev P-trend
Total
total fat (%) 18.7 17.5 18.8 14.1 o0.01 19.1 17.4 17.6 14 o0.01 17 18.4 19.2 17.1 0.01
Central
central fat (%) 21.9 22.6 26 22.5 0.27 22.7 22.6 24 22 0.60 20.1 25.9 26.9 26.7 o0.01
VAT (cm2) 71 93 121 127 o0.01 78 102 105 126 0.03 70 103 136 154 o0.01
TAT (cm2) 187 224 227 200 0.76 213 250 215 191 0.29 176 224 231 254 o0.01
waist (cm) 85 85.5 87 87 o0.01 86 85.5 87 84.2 0.89 84 87 90 92 o0.01
Peripheral
arm (%) 15.2 13.5 14.2 10.3 o0.01 15.7 13.4 13.5 10.0 o0.01 13.7 14.5 14.2 14.7 0.20
leg (%) 18.3 12.4 12.6 8.5 o0.01 18.0 12.3 12.0 8.3 o0.01 14.2 12.4 12.0 10.4 0.05
SAT (cm2) 104 94 89 63 o0.01 109 95 84 62 o0.01 87 102 86 64 0.46
naso-labial fold (mm) 10 9 9 8 o0.01 10 9 9 7.4 o0.01 9 10 10 8 0.91
tricep (mm) 9 7 7 6 o0.01 9 7 7 6 o0.01 8 8 7 7 0.02
supra-iliac crest (mm) 12 10 11 7.7 o0.01 12 10 10 7.6 o0.01 10 11.3 13 9.5 0.10
calf (mm) 8.6 7.5 5 4 o0.01 10.4 7 4.8 4 o0.01 8 6 5 4.8 o0.01
hip (cm) 94 92 92 91 o0.01 94 92 91.1 90 o0.01 93 92 93 94 0.31
Lipid parameters
triglyceride (mmol/L) 1.5 1.8 2.3 2.4 o0.01 1.7 1.8 2.4 2.4 o0.01 1.7 2.2 2.5 2.4 o0.01
total cholesterol (mmol/L) 5 5.2 5.4 5.5 0.01 5.1 5.3 5.4 5.4 0.03 5.0 5.4 5.7 5.5 0.01
HDL cholesterol (mmol/L) 1.0 1.1 1.0 0.9 o0.01 1.0 1.0 1.0 0.9 o0.01 1.0 1.0 0.9 1.0 0.01
Glycaemic parameters
glucose (mmol/L) 4.9 4.8 5.0 5.0 0.25 4.9 4.8 5.0 5.0 0.99 4.9 5.0 5.0 5.2 0.02
insulin (mIU/L) 6.0 9.0 8.0 10.9 o0.01 7.0 9.0 8.4 9.0 0.01 7.0 9.0 9.7 14.2 o0.01
C-peptide (mg/L) 1.1 1.2 1.5 2.4 o0.01 1.2 1.2 2 2.3 o0.01 1.2 1.3 2.36 4.1 o0.01
Other parameters
ALT (IU/L) 28 28 28 33 o0.01 28 29 29 32 o0.01 28 29 31 41 o0.001
AST (IU/L) 25 29 28 32 o0.01 26 27 29 31 o0.01 26 29 28 34 o0.001
testosterone (nmol/L) 22.5 22.0 19.2 18.3 o0.01 22.1 21.5 19.4 18.3 o0.01 21.9 21.0 18.3 17.2 o0.01
Data are means. VAT, visceral adipose tissue; TAT, total adipose tissue; SAT, subcutaneous adipose tissue; HDL, high-density lipoprotein; ALT, alanine
aminotransferase; AST, aspartate aminotransferase.
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adipose tissue. DEXA demonstrated an increase in the total
percentages of body fat and central fat, while no significant
differences were seen in limb fat between those with and
those without central lipohypertrophy.
Lipodystrophy severity
While lipodystrophy was frequently observed, the majority
of cases were mild to moderate (Tables 4 and 5). Severe
lipodystrophy, lipoatrophy or lipohypertrophy in at least
one site was observed in 25%, 16% and 9% of patients,
respectively. When numerical scores were attached to
lipodystrophy reports (05 none, 15mild, 25moderate,
35 severe), the mean total severity rating for patients with
any lipodystrophy was 6.1 (Table 2). Differences were seen
between treatment groups for overall severity scores. Naive
patients had the lowest overall lipodystrophy severity
ratings and PI-treated patients had the highest overall
rating as well as the highest ratings for lipoatrophy only
and lipohypertrophy only. Of the naive patients with
lipohypertrophy (21/168), 20 had abdominal lipohypertro-
phy, and of these only four were of severe intensity.
Similarly, in naive patients with lipoatrophy, either alone
or as part of a mixed phenotype (30/168), 15 patients had
two or less affected sites with the majority of the affected
sites being of mild intensity.
Lipodystrophy–associated factors
Multivariate analyses demonstrated significant associa-
tions between physician-assessed lipodystrophy, lipoatro-
phy, lipohypertrophy and a range of demographic, disease
and treatment factors (Table 3). Factors significantly
associated with the presence of any lipodystrophy, regard-
less of phenotype, were older age, CDC HIV disease
category B or C, undetectable levels of HIV RNA, extended
treatment exposure to NRTIs and any exposure to PIs.
Associated factors were similar for lipoatrophy and
lipohypertrophy; females, however, were 50% less likely
to have lipoatrophy and participants who had higher
exercise levels had a reduced likelihood of central
lipohypertrophy.
The relative associations between different antiretroviral
classes and lipodystrophy were assessed in multivariate
analyses. Increased exposure to both NRTIs and PIs was
significantly associated with significant increases in risk
for lipodystrophy, while no effect was seen with NNRTI use,
although the median length of exposure to this drug class
was relatively short (Table 6). In patients with lipoatrophy,
significant trends were seen with increased duration of
therapy with saquinavir, indinavir (IDV), nelfinavir, zalci-
tabine and stavudine (d4 T). Lipohypertrophy was signifi-
cantly associated with increased duration of therapy with
IDV, d4 T and lamivudine.
Discussion
This survey of a broad cross-section of people with HIV in
Australia has provided a comprehensive assessment of
lipodystrophy and its associated factors. The survey is the
largest published to date and, based on comparisons with
Table 4 Lipodystrophy by phenotype and severity (%)
Lipohypertrophy
Severity None Mild Moderate Severe Total
None 40 3.1 1.1 0.5 44.7
Lipoatrophy Mild 10.7 8.4 2.4 0.3 21.8
Moderate 7.9 6.3 5.1 1.5 20.8
Severe 2.5 2.8 2.8 4.5 12.9
Total 61.1 20.6 13.1 5.3 100
Figures are rounded to nearest 0.1 decimal point. Patients classified by the maximal severity rating attained for peripheral lipoatrophy and/or central
lipohypertrophy using the severity grading system described in the Methods section.
Table 5 Per cent of patients with lipodystrophy – regions affected by maximum recorded severity
Abdomen Breast Dorsocervical Lipoma Face Arms Legs Buttocks
None 61 93 96 96 55 61 58 64
Mild 21 4 2 3 23 22 21 16
Moderate 13 2 1 1 14 13 15 14
Severe 5 1 1 o1 8 4 6 6
All percentages rounded to nearest whole number.
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Table 6 Factors associated with lipodystrophy
Any lipodystrophy Abdominal adiposity Lipoatrophy
n OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age (years)
o35 331 1.0 1.0 1.0
35–39 297 1.55 (1.08, 2.22) 0.019 1.72 (1.14, 2.59) 0.010 1.34 (0.94, 1.92) 0.110
40–49 387 1.89 (1.33, 2.67) o0.001 2.50 (1.71, 3.66) o0.001 1.93 (1.37, 2.72) o0.001
Z50 188 3.20 (2.04, 5.00) o0.001 5.08 (3.26, 7.92) o0.001 2.24 (1.47, 3.42) o0.001
Gender
male 1192 1.0 1.0 1.0
female 67 0.53 (0.29, 0.98) 0.043 1.46 (0.79, 2.72) 0.232 0.44 (0.23, 0.82) 0.009
HIV disease category
A 662 1.0 1.0 1.0
B 356 2.22 (1.61, 3.07) o0.001 1.80 (1.32, 2.47) o0.001 1.99 (1.46, 2.71) o0.001
C 249 1.82 (1.26, 2.62) o0.001 1.84 (1.28, 2.64) o0.001 1.76 (1.23, 2.51) 0.002
CD4 (cells/mL)
o200 194 1.0 1.0 1.0
200–499 508 0.90 (0.59, 1.38) 0.639 0.87 (0.57, 1.32) 0.505 0.99 (0.66, 1.49) 0.959
Z500 546 0.97 (0.62, 1.52) 0.896 0.76 (0.48, 1.19) 0.228 0.96 (0.62, 1.48) 0.845
HIV RNA (log/mL)
410 000 280 1.0 1.00 1.0
501–10 000 225 1.56 (1.02, 2.39) 0.039 2.12 (1.34, 3.37) 0.001 1.52 (1.00, 2.32) 0.049
r500 619 2.28 (1.62, 3.23) o0.001 3.07 (2.10, 4.48) o0.001 2.04 (1.45, 2.87) o0.001
Exercise level
sedentary 158 1.0 1.0 1.0
low 381 1.12 (0.71, 1.76) 0.626 0.89 (0.57, 1.40) 0.626 1.25 (0.80, 1.93) 0.325
moderate 472 1.13 (0.73, 1.75) 0.586 0.79 (0.51, 1.23) 0.300 1.42 (0.93, 2.19) 0.106
high 201 0.94 (0.57, 1.56) 0.812 0.60 (0.35, 1.01) 0.054 1.11 (0.68, 1.82) 0.678
Steroid use
no 1164 1.0 1.0 1.0
yes 52 1.22 (0.60), 2.49) 0.587 0.84 (0.43, 1.65) 0.620 1.46 (0.73, 2.90) 0.286
NRTI use (months)
0 157 1.0 1.0 1.0
r57 559 1.27 (0.76, 2.13) 0.358 1.18 (0.63, 2.20) 0.607 1.47 (0.86, 2.52) 0.155
457 543 3.11 (1.84, 5.28) o0.001 1.90 (1.41, 2.56) o0.001 3.41 (1.98, 5.88) o0.001
didanosine
0 672 1.0 1.0 1.0
r12 256 1.40 (0.98, 2.01) 0.64 1.02 (0.72, 1.45) 0.906 1.36 (0.97, 1.92) 0.078
412 207 1.26 (0.86, 1.84) 0.240 1.43 (0.98, 2.10) 0.065 1.36 (0.94, 1.95) 0.099
lamivudine
0 188 1.0 1.0 1.0
r19 447 0.93 (0.57, 1.50) 0.753 0.95 (0.58, 1.55) 0.830 0.68 (0.44, 1.04) 0.076
419 500 1.15 (0.70, 1.87) 0.588 1.60 (0.97, 2.65) 0.066 1.03 (0.65, 1.61) 0.907
stavudine
0 556 1.0 1.0 1.0
r17 365 1.91 (1.31, 2.79) 0.001 1.50 (0.97, 2.31) 0.069 1.48 (1.02, 2.14) 0.040
417 414 4.28 (3.00, 6.12) o0.001 1.72 (1.15, 2.58) 0.008 2.50 (1.74, 3.59) o0.001
zalcitabine
0 933 1.0 1.0 1.0
r9 153 1.10 (0.73, 1.67) 0.652 1.27 (0.85, 1.90) 0.243 1.29 (0.87, 1.92) 0.208
49 149 0.84 (0.55, 1.29) 0.425 1.12 (0.74, 1.69) 0.604 1.63 (1.07, 2.47) 0.021
zidovudine
0 334 1.0 1.0 1.0
r20 406 1.16 (0.81, 1.66) 0.429 0.75 (0.51, 1.12) 0.158 0.68 (0.48, 0.97) 0.035
420 391 1.81 (1.26, 2.59) o0.001 1.17 (0.78, 1.12) 0.445 1.11 (0.75, 1.63) 0.598
NNRTI use (months)
0 798 1.0 1.0 1.0
r9 228 1.29 (0.89, 1.87) 0.187 1.40 (0.98, 1.99) 0.066 1.43 (1.00, 2.05) 0.052
410 232 0.87 (0.60, 1.26) 0.472 0.70 (0.48, 1.02) 0.064 1.04 (0.73, 1.49) 0.822
delavirdine
0 1072 1.0 1.0 1.0
r11 23 0.99 (0.37, 2.62) 0.979 1.33 (0.50, 3.56) 0.571 2.41 (0.86, 6.75) 0.094
411 20 3.16 (1.10, 9.10) 0.032 1.63 (0.59, 4.52) 0.344 1.09 (0.37, 3.19) 0.880
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the Australian HIV Observational Database, the sample is
representative of the HIV epidemic in Australia in terms of
gender, age, treatment exposure and disease stage [18]. The
data provide a clearer picture of this phenomenon,
including a comprehensive analysis of associated factors
by phenotype (Table 6).
While the prevalence of lipodystrophy was higher in
those patients taking PIs, it was also seen in patients who
had been treated for HIV, but who were PI-naive and also,
albeit less frequently, in treatment-naive patients. While
these findings in treatment-naive patients may be some-
what reflective of the subjective nature of the definition of
lipodystrophy used, their extent suggests that causative
mechanisms apart from antiretroviral therapy, may need to
be considered, or that some conditions such as wasting or
age-associated obesity may mimic some aspects of
lipoatrophy and lipohypertrophy, respectively.
The correlates established in this survey between
clinician assessment and body composition assessment
using DEXA, single cut abdominal CT and skin fold
measurements provide added support for their use in
determining lipodystrophy presence and severity. Similarly,
physician assessment of the presence and severity of
lipodystrophy using a subjective tool correlated with
differences in body fat quantity and patterns of fat
deposition.
Limitations to study
There are inherent limitations in this study. While the
proportion of caucasians and women included is repre-
sentative of the HIV epidemic in Australia, interpretation of
the results must be kept within the context of white males.
The large number of geographically diverse recruiting sites
and personnel involved in the patient assessment increases
the prospect of operator differences in the assessment of
the severity of body fat changes, questionnaire adminis-
tration, anthropometry and laboratory methods. The
lipodystrophy questionnaire used in this study has been
tested in previous surveys, but severity results must be
interpreted with a degree of caution in an observational
study like this due to the subjective nature of the rating
process. Some other researchers have utilized a more
objective severity grading system than that used in this
study. While there would appear to be merit in this
approach, the superiority of either method is yet to be
efavirenz
0 1071 1.0 1.0 1.0
r3 36 0.91 (0.42, 1.93) 0.797 0.80 (0.35, 1.79) 0.584 1.75 (0.73, 4.20) 0.209
43 28 1.54 (0.64, 3.76) 0.334 1.07 (0.45, 2.54) 0.344 0.97 (0.34, 2.74) 0.955
nevirapine
0 769 1.0 1.0 1.0
r9 187 1.25 (0.85, 1.84) 0.266 1.23 (0.83, 1.80) 0.298 0.94 (0.63, 1.39) 0.748
49 177 1.07 (0.72, 1.58) 0.752 0.68 (0.45, 1.04) 0.074 1.05 (0.73, 1.53) 0.777
PI use (months)
0 407 1.0 1.0 1.0
r22 451 1.82 (1.29, 2.58) 0.001 1.78 (1.24, 2.57) 0.002 1.71 (1.21, 2.43) 0.002
422 401 3.57 (2.41, 5.28) o0.001 3.07 (2.09, 4.50) o0.001 3.08 (2.10, 4.50) o0.001
indinavir
0 641 1.0 1.0 1.0
r15 248 1.11 (0.78, 1.58) 0.550 1.19 (0.81, 1.73) 0.373 1.23 (0.87, 1.74) 0.240
415 246 2.38 (1.67, 3.39) o0.001 1.55 (1.07, 2.23) 0.020 3.51 (2.41, 5.09) o0.001
nelfinavir
0 854 1.0 1.0 1.0
r7 136 0.96 (0.62, 1.49) 0.850 1.36 (0.87, 2.11) 0.171 1.01 (0.67, 1.52) 0.965
47 145 1.49 (0.98, 2.26) 0.059 1.00 (0.65, 1.55) 0.994 1.73 (1.14, 2.64) 0.010
ritonavir
0 870 1.0 1.0 1.0
r12 129 1.84 (1.19, 2.85) 0.006 1.40 (0.89, 2.21) 0.140 1.92 (1.20, 3.08) 0.007
412 136 1.08 (0.70, 1.69) 0.721 1.46 (0.90, 2.37) 0.123 1.03 (0.63, 1.69) 0.892
saquinavir
0 636 1.0 1.0 1.0
r15 254 0.85 (0.57, 1.25) 0.405 1.18 (0.78, 1.78) 0.424 1.66 (1.16, 2.37) 0.005
415 245 1.20 (0.81, 1.79) 0.359 1.27 (0.75, 2.14) 0.374 2.84 (1.97, 4.11) o0.001
All variables were included in the analysis, statistically significant variables (in bold) were included in the final model.
Table 6 (Continued)
Any lipodystrophy Abdominal adiposity Lipoatrophy
n OR (95% CI) p OR (95% CI) p OR (95% CI) p
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established [5]. Further, the questionnaire utilized was
designed to assess one directional fat changes, specifically,
peripheral lipoatrophy and central lipohypertrophy. This
design was based on observations made up to that time
about the fat changes seen with the syndrome. While
provision was made within the questionnaire for the
clinician to make comment about changes seen, we were
not able to examine in detail any instances where there
may have been fat gain peripherally or fat loss centrally.
While anecdotally these events are rarely seen in this
syndrome, it is clear that in future studies, bi-directional
measures should be included.
Local laboratories were used for all metabolic para-
meters. Although all conformed to national laboratory
accreditation standards, some intralaboratory differences
may result. Calculations for abdominal fat assessed by CT
were performed locally using standardized methods by
staff experienced in this methodology. While all of these
facilities were experienced in the techniques requires for
the study and all used a standardized protocol, no central
reading facilities were utilized and it is likely that some
interoperator differences may have occurred.
Comparisons with other studies
This study has demonstrated similar lipodystrophy pre-
valence rates for the overall cohort and for the protease
inhibitor-experienced group to those seen in other
published cohorts. The identification of lipodystrophy in
treatment-naive patients within a survey of this type is
new, however. The identification of lipodystrophy in this
group is somewhat surprising given the wealth of data
linking lipodystrophy with antiretroviral therapy. It is
unclear whether this group represent another aspect of the
syndrome or whether it, in fact, either reflects the
sensitivity and specificity of the diagnostic methods used,
or is a manifestation of the age or stage of HIV disease of
this group. As most previous lipodystrophy prevalence
surveys have specifically studied patients already taking
antiretrovirals, this finding may simply stem from a
difference in study designs.
This study also provides support for a clinical diagnosis
of both the presence and severity of lipodystrophy using
DEXA, CT and anthropometry to quantify lipodystrophic
changes, especially when examining specific phenotypes,
although the results in antiretroviral-naive subjects may
provide an estimate of the magnitude of false positive rates
for these tests if this syndrome is truly related to drug
toxicity. There have been limited published data, to date,
examining the impact of lipodystrophy on central fat,
measured by CT. In patients with increasing severity of
central lipohypertrophy increased levels of visceral adipose
tissue were seen alongside increased umbilical waist
circumference. Conversely, diagnosis of lipoatrophy was
associated with diminished levels of subcutaneous tissue
and decreased skin-fold thickness. All clinician diagnoses of
lipodystrophy in this survey were based on criteria that
included an assessment of both phenotype and severity. This
is the largest study to examine associations with increasing
severity of lipodystrophy rather than the presence or
absence of the condition. Disturbingly, the survey demon-
strated strong associations between visceral adiposity,
increased age and increased lipid and glycaemic parameters,
suggesting that factors associated with accelerated coronary
artery disease, while perhaps not syndrome specific, may be
phenotype specific as this clustering of associated factors
was not seen to the same extent in patients with
lipoatrophy. This is the first time that an association has
been made between lipodystrophy and elevated alanine
aminotransferase, aspartate aminotransferase and decreased
testosterone levels. It has been established that hepatotoxi-
city, usually independent of immune status is associated
with long-term exposure to antiretroviral medications.
Drugs implicated include the NRTIs, the NNRTI nevirapine,
and certain PIs. Given the lack of congruence between the
drugs associated with lipodystrophy in this survey and
those associated with hepatoxicity in the literature, it is
clearly beyond the scope of this study to speculate on issues
of causality, but it is clear that studies of lipodystrophy and
hepatocyte function are warranted. Given the established
role of sex hormones in lipid regulation, these findings
support the notion that factors other than, or in addition to,
mitochondrial toxicity may be relevant in the aetiology of
this syndrome. It may be of significance that this study and
others have identified disparities in lipodystrophy preva-
lence between gender groups, increased age and lipody-
strophy. In addition, lower levels of HIV RNA have been
described for the first time in all lipodystrophy phenotypes.
This finding supports the purported link with antiretroviral
therapy and lipodystrophy.
Conclusion
This large survey of demonstrates that lipodystrophy is a
common phenomenon in patients with HIV, overwhel-
mingly more frequent in those who have been treated with
antiretrovirals. The majority of cases of lipodystrophy were
either mild or moderate in severity with a mixed phenotype
being the predominant presentation.
Lipodystrophy is significantly associated with increased
age, symptomatic HIV disease, effective viral suppression,
and increased duration of therapy with both NRTIs and PIs.
These findings are suggestive of a multifactorial aetiology
for lipodystrophy. This study also suggests relationships
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between different lipodystrophy phenotypes and specific
ARV agents, although definitive associations cannot be
deduced from this type of survey.
Acknowledgements
The National Centre in HIV Epidemiology and Clinical
Research is funded by the Commonwealth Department of
Health and Ageing. The study was supported in part by
grants from Abbott, Roche and Bristol-Myers Squibb. The
authors would like to acknowledge the time and commit-
ment of the patients who participated in the study.
Other investigators of the Australian Lipodystrophy
Prevalence Survey were: Geraldine Dolan, Robert Fielden,
Karen MacRae, Helen Wood (St. Vincent’s Hospital,
Sydney), Robert McFarlane, William Genn, Janet Kidd
(407 Doctors, Sydney), Martyn French, Jenny Skett
(Department of Clinical Immunology, Royal Perth Hospi-
tal), Anne Mijch, Jennifer Hoy, Melissa Bryant, Claire
McCormack (Alfred Hospital, Melbourne), John Chuah,
Sally Jacobs (Gold Coast Sexual Health Clinic, Miami),
Mark Bloch, Chris Duncombe, David Austin, Dick Quan
(Holdsworth House General Practice, Sydney), Robert
Finalyson, Neil Bodsworth, Cathy Pell, Robyn Richardson
(Taylor Square Private Clinic, Sydney), Michael Rawlinson,
David Sowden, Alan Walker (Nambour Sexual Health
Clinic), Jo Groves, Kathy Petoumenos, Terry Sharkey, Jenni
Mitchell (National Centre in HIV Epidemiology and Clinical
Research, University of New South Wales, Sydney) Norm
Roth, Andrew Buchanan (Prahran Market Clinic, Mel-
bourne), Jonathan Anderson (Carlton Clinic, Melbourne),
Tony Allworth, Janelle Zillman (Royal Brisbane Hospital),
Hugo Ree, Ken Clare (AIDS Medical Unit, Brisbane), Keiran
Mutimer, Nikki Keefe (SHADES, Lismore), Dominic Dwyer,
Margaret Fordham (Westmead Hospital, Sydney).
References
1 Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ,
Cooper DA. A syndrome of peripheral lipodystrophy and
insulin resistance in patients receiving HIV protease inhibitors.
AIDS 1998 May 7; 12 (7): F51–F58.
2 Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I,
Falloon J. Visceral abdominal-fat accumulation associated
with use of indinavir. Lancet 1998; 351: 871–875.
3 Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. ‘Buffalo
hump’ in men with HIV-1 infection. Lancet 1998; 351:
867–870.
4 Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ,
Cooper DA. Diagnosis, prediction and natural course of HIV
protease inhibitor-associated lipodystrophy, hyperlipidaemia
and diabetes mellitus. Lancet 1999; 353: 2893–2899.
5 Lichtenstein K, Ward D, Moorman A et al. Clinical assessment
of HIV-associated lipodystrophy in an ambulatory population.
AIDS 2001; 15: 1389–1398.
6 Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M,
Vilmer E, Levy-Marchal C. Clinical and metabolic presentation
of the lipodystrophic syndrome in HIV-infected children. AIDS
2000; 14 (14): 2123–2128.
7 Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N,
Grinspoon S. Fasting hyperinsulinemia and changes in regional
body composition in human immunodeficiency virus-infected
women. J Clin Endocrinol Metab 1999; 84 (6): 1932–1937.
8 Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V,
O’Shaughnessy MV, Montaner JS. Lipodystrophy-associated
morphological, cholesterol and triglyceride abnormalities in a
population-based HIV/AIDS treatment database. AIDS 2001
January 26; 15 (2): 231–239.
9 Walli R, Herfort O, Michl GM et al. Treatment with protease
inhibitors associated with peripheral insulin resistance and
impaired glucose tolerance in HIV-1 infected patients. AIDS
1998; 12 (15): F167–F173.
10 Henry K, Melroe H, Huebsch J et al. Severe premature coronary
artery disease with protease inhibitors. Lancet 1998; 351: 1328.
11 Boubaker K, Sudre P, Flepp M et al. Hyperlactatemia and
antiretroviral therapy in the Swiss HIV Cohort Study. Clin Infect
Dis 2001; 33 (11): 1931–1937.
12 Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of
protease inhibitors on hyperglycemia, hyperlipidemia, and
lipodystrophy: a 5-year cohort study. Arch Intern Med 2000
July 10; 160 (13): 2050–2056.
13 Thiebaut R, Daucourt V, Mercie P et al. Lipodystrophy,
metabolic disorders, and human immunodeficiency virus
infection. Aquitaine Cohort, France, 1999. Clin Infect Dis 2000;
31 (6): 1482–1487.
14 Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution
evaluated by computed tomography and metabolic
abnormalities in patients undergoing antiretroviral therapy:
preliminary results of the LIPOCO study. AIDS 2000; 14: 37–49.
15 Kingsley L, Smit E, Riddler S et al. Prevalence of lipodystrophy
and metabolic abnormalities in the Multicenter AIDS Cohort
Study (MACS). 8th Conference on Retroviruses and Opportunistic
Infections. Chicago, February 2001 [Abstract 538].
16 Jeppeson J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride
concentration and ischemic heart disease: an eight year follow-up
in the Copenhagen male study. Circulation 1998; 97: 1029–1036.
17 National Centre in HIV Epidemiology and Clinical Research.
HIV/AIDS, viral hepatitis and sexually transmissible infections
in Australia, Annual Surveillance Report 2002. Sydney, NSW,
National Centre in HIV Epidemiology and Clinical Research,
The University of New South Wales, 2002.
18 The Australian Observational Database. Rates of combination
antiretroviral treatment change in Australia, 1997–2000. HIV
Med 2002; 3: 28–36.
HIV lipodystrophy in Australia 301
r 2003 British HIV Association HIV Medicine (2003) 4, 293–301
